SWX/MRNA (SWX/MRNA)

SIX Swiss Exchange: SWX/MRNA · CHF

CHF 183

+0.00 (0.0%)· Recorded snapshot

Market cap	72.2B
Revenue (ttm)	1.8B
Net income (ttm)	-2.5B
EPS (ttm)	-CHF 6.56

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 1.8B
Net income (ttm): -2.5B
EPS (ttm): -CHF 6.56
Market cap: 72.2B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-03 14:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-39

P25 n/aP50 n/aP75 n/a

ROIC-76

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SWX/MRNA indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

USD

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	CHF
Country	United States
Country code	CH
Earnings date	2026-11-06
Employees	4,700
Employees change	-1,100
Employees growth	-18.97%
Enterprise value	CHF 67.6B
Exchange	SIX Swiss Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-08-21
Fiscal year end	December
Founded	2010
Industry	Biotechnology
Is primary listing	No
ISIN number	US60770K1079
Last refreshed	2026-11-03
Market cap	CHF 72.2B
Next earnings date	2026-11-06
Price	CHF 182.66
Price currency	CHF
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-02
Symbol	swx/MRNA
Website	https://www.modernatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.59%
EV/Sales	37.05x
FCF / EV yield	-1.49%
FCF yield	-1.39%
Industry forward P/E	85.45x
P/B ratio	13.22x
P/S ratio	40.12x
Price / tangible book value	13.54x
Sector forward P/E	19.93x
Sector P/E	34.45x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-109.34%
EBITDA margin	-98.52%
Gross margin	-66.02%
Operating margin	-109.34%
Pretax margin	-138.55%
Profit margin	-141.43%
Profit per employee	CHF -541,704
Revenue per employee	CHF 383,026
ROA	-13.26%
ROA (5Y)	6.72%
ROCE	-28.91%
ROE	-39%
ROE (5Y)	22.02%
ROIC	-75.99%
ROIC (5Y)	40.43%
SBC / revenue	20.74%
Tax / revenue	2.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth quarters	1
Net income growth years	2
Revenue growth	-27.62%
Revenue growth (Q)	2.11%
Revenue growth (QoQ)	-62.72%
Revenue growth 3Y	-40.64%
Revenue growth 5Y	-20.51%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	CHF -138.2M
Depreciation and amortization	CHF 197.5M
EBIT	CHF -2B
EBITDA	CHF -1.8B
EPS	CHF -6.56
Financing cash flow	CHF 493.7M
Free cash flow	CHF -1B
Free cash flow minus SBC	CHF -1.4B
Gross profit	CHF -1.2B
Income taxes	CHF 51.7M
Investing cash flow	CHF 731.2M
Net borrowing	CHF 473.7M
Net cash flow	CHF 357.9M
Net income	CHF -2.5B
Operating cash flow minus SBC	CHF -1.2B
Operating income	CHF -2B
Revenue	CHF 1.8B
Stock-based compensation	CHF 373.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.62
Book value per share	CHF 13.69
Debt / equity	0.19
Goodwill	CHF 42.6M
Interest coverage	-58
Long-term assets	CHF 4.1B
Long-term liabilities	CHF 1.3B
Net cash (debt)	CHF 4.5B
Net cash / market cap	6.29%
Net cash growth	-16.87%
Net debt / equity	-0.83
Piotroski F-Score	2
Property, plant and equipment	CHF 2.3B
Shareholders' equity	CHF 5.5B
Tangible book value	CHF 5.3B
Tangible book value per share	CHF 13.37
Total assets	CHF 8.9B
Total cash	CHF 4.2B
Total debt	CHF 1B
Total liabilities	CHF 3.4B

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	CHF 4.8B
Current liabilities	CHF 2.1B
Current ratio	2.29
Inventory turnover	14.23
Net working capital	CHF -1.5B
Quick ratio	2.07
Working capital	CHF 2.7B
Working capital turnover	0.46

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.94%
Shareholder yield	-1.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	CHF 82.16
1D price change	0%
1M price change	12.5%
1M total return	12.5%
1W price change	12.78%
1W total return	12.78%
20-day SMA	CHF 177.93
200-day SMA	CHF 71.09
3M price change	300.04%
3M total return	300.04%
50-day SMA	CHF 150.59
50-day SMA vs 200-day SMA	50over200
52-week high	CHF 203.00
52-week high date	2026-10-21
52-week low	CHF 19.65
52-week low date	2025-12-08
6M price change	396.63%
6M total return	396.63%
All-time high	CHF 203.00
All-time high date	2026-10-21
All-time low	CHF 19.65
All-time low date	2025-12-01
Average true range (ATR)	CHF 7.38
Average volume	1.7
Change from 52-week high	-10.02%
Change from 52-week low	829.57%
Change from all-time high	-10.02%
Change from all-time low	829.57%
Monthly RSI	0
Previous close	CHF 182.66
Price vs 150-day SMA	122.32%
Price vs 20-day SMA	2.66%
Price vs 200-day SMA	156.93%
Price vs 50-day SMA	21.3%
Relative volume	4.85
RSI	57.24
Sharpe ratio	2.15
Sortino ratio	7.48
Weekly RSI	84.47
YTD price change	642.22%
YTD total return	642.22%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	372M
Shares change (QoQ)	0.76%
Shares change (YoY)	1.94%
Shares held by insiders	6.74%
Shares held by institutions	80.45%
Short ratio	1.5 days

Deeper analysis on SWX/MRNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SWX/MRNA report

Is a complete SWX/MRNA research report available?

No complete published report is available for swx/MRNA (SWX/MRNA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

SWX/MRNA (SWX/MRNA)

Price

Financial snapshot

Fair-value bridge

Latest news · SWX/MRNA

Valuation

Profitability

Balance sheet

Next earnings

Sector percentile context

All SWX/MRNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SWX/MRNA

Frequently asked questions